MC4R and obesity due to melanocortin 4 receptor deficiency: A phase II clinical trial with setmelanotide in patients with rare genetic disorders of obesity has completed recruitment (ClinicalTrials.gov identifier: NCT03013543).75 It involves investigating once-daily setmelanotide injections in patients ≥6 years across various cohorts of patients with several defects in the MC4R pathway.